{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:58:57Z","timestamp":1792198737821,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpain.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pain"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jpain.2023.06.008","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T20:37:19Z","timestamp":1686861439000},"page":"1994-2002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Trends in Prescribing of Non-steroidal Anti-inflammatory Medications in the US Ambulatory Care Setting From 2006 to 2016"],"prefix":"10.1016","volume":"24","author":[{"given":"Shailina","family":"Keshwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsuan","family":"Lo-Ciganic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonkyeong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole E.","family":"Smolinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Hincapie-Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpain.2023.06.008_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0234","article-title":"Changes in opioid use after florida\u2019s restriction law for acute pain prescriptions","volume":"3","author":"Hincapie-Castillo","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpain.2023.06.008_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2147\/JPR.S129553","article-title":"Secular trends in opioid prescribing in the USA","volume":"10","author":"Pezalla","year":"2017","journal-title":"J Pain Res"},{"key":"10.1016\/j.jpain.2023.06.008_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.japh.2020.09.013","article-title":"Effects of hydrocodone rescheduling on opioid use outcomes: a systematic review","volume":"61","author":"Usmani","year":"2021","journal-title":"J Am Pharm Assoc"},{"key":"10.1016\/j.jpain.2023.06.008_bib4","unstructured":"Prescription Opioid Trends in the United States. IQVIA. Available at: https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports\/prescription-opioid-trends-in-the-united-states Accessed March 29, 2022."},{"key":"10.1016\/j.jpain.2023.06.008_bib5","first-page":"1","article-title":"Prevalence of prescription pain medication use among adults: United States, 2015\u20132018","author":"Hales","year":"2020","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.jpain.2023.06.008_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/phar.2488","article-title":"trends in prescription nonsteroidal anti-inflammatory drug use among patients with cardiovascular disease, 1988-2016","volume":"41","author":"Hwang","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jpain.2023.06.008_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.13383","article-title":"Trends in use of prescription nonsteroidal anti-inflammatory medications before vs after implementation of a florida law restricting opioid prescribing for acute pain","volume":"4","author":"Keshwani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpain.2023.06.008_bib8","first-page":"766","article-title":"Pharmacologic therapy for acute pain","volume":"87","author":"Blondell","year":"2013","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jpain.2023.06.008_bib9","unstructured":"FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. FDA. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory Accessed March 13, 2021."},{"key":"10.1016\/j.jpain.2023.06.008_bib10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","article-title":"Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE\/APLAR\/APSDE\/APSH\/APSN\/PoA recommendations","volume":"69","author":"Szeto","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jpain.2023.06.008_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.7326\/0003-4819-109-5-359","article-title":"Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons","volume":"109","author":"Griffin","year":"1988","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpain.2023.06.008_bib12","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(94)90185-6","article-title":"Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs","volume":"343","author":"Langman","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2023.06.008_bib13","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0140-6736(09)60938-7","article-title":"Peptic ulcer disease","volume":"374","author":"Malfertheiner","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jpain.2023.06.008_bib14","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/hep.20948","article-title":"Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study","volume":"4","author":"Larson","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jpain.2023.06.008_bib15","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/j.1572-0241.2007.01388.x","article-title":"Population-based surveillance for acute liver failure","volume":"102","author":"Bower","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jpain.2023.06.008_bib16","unstructured":"Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry. FDA. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/development-non-opioid-analgesics-acute-pain-draft-guidance-industry Accessed March 29, 2022."},{"issue":"3","key":"10.1016\/j.jpain.2023.06.008_bib17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/pds.3335","article-title":"A survey of adult awareness and use of medicine containing acetaminophen","volume":"22","author":"Boudreau","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2023.06.008_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/pds.3463","article-title":"Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population","volume":"23","author":"Zhou","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2023.06.008_bib19","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jpain.2022.01.006","article-title":"Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014-2018","volume":"23","author":"Gorfinkel","year":"2022","journal-title":"J Pain"},{"key":"10.1016\/j.jpain.2023.06.008_bib20","unstructured":"NAMCS micro-data file documentation. CDC. Available at: https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/doc2015.pdf Accessed April 1, 2021."},{"issue":"6","key":"10.1016\/j.jpain.2023.06.008_bib21","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1370\/afm.2474","article-title":"National trends in primary care visit use and practice capabilities, 2008\u20132015","volume":"17","author":"Rao","year":"2019","journal-title":"Ann Fam Med"},{"issue":"1","key":"10.1016\/j.jpain.2023.06.008_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/jcm9010083","article-title":"Trends, patient and prescriber characteristics in gabapentinoid use in a sample of united states ambulatory care visits from 2003 to 2016","volume":"9","author":"Zhou","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jpain.2023.06.008_bib23","unstructured":"Wang F., Shin H.-C. SAS\u00ae model selection macros for complex survey data using PROC SURVEYLOGISTIC\/SURVEYREG. Available at: https:\/\/www.norc.org\/PDFs\/CESR%20Docs\/MWSUG-2011-SA02.pdf Accessed December 9, 2022."},{"key":"10.1016\/j.jpain.2023.06.008_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16475","article-title":"Patterns in nonopioid pain medication prescribing after the release of the 2016 guideline for prescribing opioids for chronic pain","volume":"5","author":"Goldstick","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpain.2023.06.008_bib25","doi-asserted-by":"crossref","first-page":"697","DOI":"10.15585\/mmwr.mm6626a4","article-title":"Vital signs: changes in opioid prescribing in the United States, 2006\u20132015","volume":"66","author":"Guy","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jpain.2023.06.008_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/08897077.2017.1389798","article-title":"Effect of a high dosage opioid prior authorization policy on prescription opioid use, misuse, and overdose outcomes","volume":"39","author":"Hartung","year":"2018","journal-title":"Subst Abus"},{"key":"10.1016\/j.jpain.2023.06.008_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jemermed.2016.07.120","article-title":"Changes in provider prescribing patterns after implementation of an emergency department prescription opioid policy","volume":"52","author":"Osborn","year":"2017","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jpain.2023.06.008_bib28","unstructured":"U.S. Opioid Dispensing Rate Maps. CDC. Available at: https:\/\/www.cdc.gov\/drugoverdose\/rxrate-maps\/index.html Accessed November 7, 2022."},{"key":"10.1016\/j.jpain.2023.06.008_bib29","first-page":"63","article-title":"Pharmacologic therapy for acute pain","volume":"104","author":"Amaechi","year":"2021","journal-title":"Am Fam Physician"},{"issue":"5","key":"10.1016\/j.jpain.2023.06.008_bib30","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjms.2016.08.028","article-title":"Overuse and misperceptions of nonsteroidal anti-inflammatory drugs in the United States","volume":"352","author":"Cryer","year":"2016","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jpain.2023.06.008_bib31","unstructured":"All manufacturers of prescription combination drug products with more than 325 mg of acetaminophen have discontinued marketing. FDA. Available at: https:\/\/www.fda.gov\/drugs\/information-drug-class\/all-manufacturers-prescription-combination-drug-products-more-325-mg-acetaminophen-have-discontinued Accessed May 9, 2022."},{"key":"10.1016\/j.jpain.2023.06.008_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/039463201302600132","article-title":"Overuse of prescription and OTC non-steroidal anti-inflammatory drugs in patients with rheumatoid arthritis and osteoarthritis","volume":"26","author":"Cavagna","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jpain.2023.06.008_bib33","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/pds.4391","article-title":"Exceeding the daily dosing limit of nonsteroidal anti-inflammatory drugs among ibuprofen users","volume":"27","author":"Kaufman","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jpain.2023.06.008_bib34","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1080\/14656566.2022.2133601","article-title":"Pharmacological considerations when treating hypertensive patients for osteoarthritis","volume":"23","author":"Piszczatoski","year":"2022","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jpain.2023.06.008_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7664","article-title":"Assessment of physician prescribing of muscle relaxants in the United States, 2005\u20132016","volume":"3","author":"Soprano","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpain.2023.06.008_bib36","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1093\/ajh\/hpy118","article-title":"Use of prescription medications that potentially interfere with blood pressure control in new-onset hypertension and treatment-resistant hypertension","volume":"31","author":"Hwang","year":"2018","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jpain.2023.06.008_bib37","unstructured":"Most U.S. adults unaware that over-the-counter pain relievers may increase blood pressure. AHA. Available at: https:\/\/newsroom.heart.org\/news\/most-u-s-adults-unaware-that-over-the-counter-pain-relievers-may-increase-blood-pressure Accessed May 9, 2022."},{"key":"10.1016\/j.jpain.2023.06.008_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1471-2261-12-93","article-title":"Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension","volume":"12","author":"Aljadhey","year":"2012","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jpain.2023.06.008_bib39","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.amjmed.2011.02.025","article-title":"Harmful effects of NSAIDs among patients with hypertension and coronary artery disease","volume":"124","author":"Bavry","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jpain.2023.06.008_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12013-013-9791-5","article-title":"Non-steroidal anti-inflammatory drugs and hypertension","volume":"69","author":"Zheng","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"10.1016\/j.jpain.2023.06.008_bib41","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/CIRCULATIONAHA.121.058068","article-title":"Acetaminophen-Induced hypertension: where have all the \u201cSafe\u201d analgesics gone?","volume":"145","author":"Smith","year":"2022","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jpain.2023.06.008_bib42","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCULATIONAHA.121.056015","article-title":"Regular acetaminophen use and blood pressure in people with hypertension: the PATH-BP trial","volume":"145","author":"MacIntyre","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jpain.2023.06.008_bib43","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1093\/eurjpc\/zwac112","article-title":"Effect of acetaminophen on blood pressure: a systematic review and meta-analysis of randomized controlled trials","volume":"29","author":"Gupta","year":"2022","journal-title":"Eur J Prev Cardiol"}],"container-title":["The Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152659002300442X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152659002300442X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:12:40Z","timestamp":1761509560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152659002300442X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S152659002300442X"],"URL":"https:\/\/doi.org\/10.1016\/j.jpain.2023.06.008","relation":{},"ISSN":["1526-5900"],"issn-type":[{"value":"1526-5900","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Prescribing of Non-steroidal Anti-inflammatory Medications in the US Ambulatory Care Setting From 2006 to 2016","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pain","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpain.2023.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 \u00a9 Published by Elsevier Inc. on behalf of United States Association for the Study of Pain, Inc","name":"copyright","label":"Copyright"}]}}